Adaptive and Collaborators to Present More than 30 Abstracts at 2023 ASH Annual Meeting

Read More

Timeline

Scroll through Adaptive Biotechnologies’ timeline and learn how we have arrived at the precipice of transforming medicine. Our milestones show how we are harnessing the natural capabilities of the immune system to develop clinical diagnostics and therapeutics.

2009

2009

Propelling the Understanding of Adaptive Immunity

Preview of 'blood' Journal

Dr. Harlan Robins, professor at the Fred Hutchinson Cancer Research Institute, and colleagues develop the first immunosequencing technology to profile the T-cell immune repertoire at scale and with precision, which had never before been possible.

2009

Adaptive is Born

Harlan and his brother, Chad Robins, found Adaptive TCR to meet the demand for this technology from academic institutions around the world.

2010

2010

Unveiling the Brilliance of the Adaptive Immune System

immunoSEQ Packaging

Adaptive launches its first research product, immunoSEQ. Scientists worldwide now have this sophisticated tool to profile and monitor the adaptive immune response, to propel their research in many diseases, and to understand the immune response to therapies.

“We have delivered the Hubble Telescope as compared to a pair of binoculars to look at the adaptive immune system.”
Chad Robins, Chief Executive Officer, Co-founder, Chairman of the Board

2012

2012

A New HQ in One of the World’s Biggest Tech Hubs

Exterior of Adaptive's original Seattle HQ

Adaptive sets up shop in South Lake Union, in the heart of Seattle.

2014

2014

Adaptive Reaches 50 Publications

Adaptive’s technology propels research forward in oncology, hematology, infectious disease, transplantation, and autoimmunity, enabling a paradigm shift in understanding human immunology.

2015

2015

A Giant Step Forward in Developing Clinical Diagnostics and Therapeutics

Adaptive develops new technology to map T cells to the antigens they target, providing the capability to see what diseases the immune system responds to and setting the stage for novel diagnostic tests. New technology to pair the chains of T-cell receptors (TCRs) helps identify which ones have the greatest therapeutic potential.

2015

Honored Among Goldman Sachs’ 100 Most Intriguing Entrepreneurs

Chad and Haran Robins

Chad and Harlan are honored by Goldman Sachs for their groundbreaking technology and the promise Adaptive can bring to the future of medicine.

2015

100 Publications

Scientists across disease areas continue to propel their research, elucidating the immune response in diseases as varied as multiple sclerosis, metastatic melanoma, and peanut allergy.

2016

2016

200 Publications and Counting

Adaptive reaches 200 publications based on our technology.

2017

2017

Adaptive Partners with Microsoft to Map the Human Immune System

Adaptive biotechologies and microsoft

Adaptive partners with Microsoft, combining their AI and machine-learning capabilities with our platform to map TCRs to the diseases they detect at scale. The goal is to develop blood tests for early and accurate detection of many diseases.

2018

2018

First Immunosequencing–Based Diagnostic Cleared by FDA

Preview of clonoSEQ Mrd Report

clonoSEQ receives FDA clearance for the detection and monitoring of measurable residual disease (MRD) in patients with multiple myeloma and acute lymphoblastic leukemia.

2019

2019

Adaptive and Genentech Partner to Develop Personalized Cellular Therapies

Adaptive Biotechnologies and Genentech: A Member of the Roche Group

Adaptive and Genentech join forces to develop shared and personalized T cell–based therapies for cancer patients, validating the therapeutic potential of Adaptive’s platform.

2019

clonoSEQ Covered by Medicare

Doctor speaking with patient

Patients with certain blood cancers are ensured access by Medicare for MRD assessment to support more personalized treatment decisions. This paves the way for further coverage by private payers.

2019

Adaptive Goes Public

Harlan and Chad Robins at Nasdaq during the IPO

In one of the biggest biotech IPOs of the year, Harlan and Chad Robins ring the Nasdaq opening bell as Adaptive is listed under the ticker symbol ADPT.

2020

2020

500 Publications and Building

From narcolepsy to ovarian cancer. From HIV to SARS-CoV-2. From the healthy baseline of the immune repertoire to kidney transplantation. Adaptive continues to propel the understanding of the smallest details and the biggest insights of immune response.

2020

Decoding the Immune Response to COVID-19

Adaptive, in partnership with Microsoft, points its platform against COVID-19. They share the data freely with researchers around the world to inform novel diagnostics, therapeutics, and vaccines via ImmuneCODE, the largest database ever developed of T-cell immune responses to this virus.

2020

Enabling a New Way to Measure Immunity

Adaptive launches immunoSEQ T-MAP COVID, a new tool for researchers that measures the T-cell response to vaccines in development and tracks the persistence of the responses over time.

2020

clonoSEQ Expands to Third Indication for Chronic Lymphocytic Leukemia

For the first time, the FDA clears clonoSEQ for use as a blood-based test. Patients living with the most common type of leukemia have a new and convenient way to get answers about their disease and remission status.

2020

The First-Ever T Cell–Based Diagnostic Test

Adaptive launches T-Detect COVID, a novel diagnostic test for patients that uses the T cell as a marker to indicate recent or past infection. This is a small step for Adaptive and a large step towards Adaptive’s and Microsoft’s ultimate vision to develop T cell–based tests for early and accurate detection of many diseases from a single blood sample.

What's Next

What's Next

The Future of Immune Medicine

Adaptive is powering the age of immune medicine and propelling a paradigm shift in healthcare. The combination of our unique approach and the near-infinite applications of immune medicine provide opportunities to make a difference in the lives of people living with many different diseases, both now and in the future.

This is just the beginning of the story.